Rhinomed Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RHNMF research report →
Companywww.rhinomed.global
Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. The company's products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab.
- CEO
- Michael Johnson
- IPO
- 2017
- HQ
- Cremorne, VIC, AU
Price Chart
Valuation
- Market Cap
- $5.45M
- P/E
- -1.05
- P/S
- 1.54
- P/B
- -1.78
- EV/EBITDA
- -1.90
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -2.55%
- Op Margin
- -133.67%
- Net Margin
- -145.98%
- ROE
- 1591.14%
- ROIC
- 2753.17%
Growth & Income
- Revenue
- $7.47M · -17.93%
- Net Income
- $-10,908,255 · -106.56%
- EPS
- $-0.04 · -89.11%
- Op Income
- $-9,410,193
- FCF YoY
- -729.57%
Performance & Tape
- 52W High
- $0.07
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.03
- Beta
- 0.88
- Avg Volume
- 42.81K
Get TickerSpark's AI analysis on RHNMF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RHNMF Coverage
We haven't published any research on RHNMF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RHNMF Report →